A random forest model to predict the efficacy of anti-PD-1/PD-L1 monoclonal antibody in lung adenocarcinoma

被引：0
|
作者：
Xie, Tongji
Li, Yan
Yang, Lin
Wu, Lige
Yuan, Hanqi
Ying, Jianming
Li Junling
Xing, Puyuan
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Dept Pathol, State Key Lab Mol Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20558
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [12] Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
    Wang, Luyao
    Ma, Qingxia
    Yao, Ruixue
    Liu, Jia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 79
  • [13] Exosomal PD-L1 and T lymphocyte status predict the effect of anti-PD-1 therapy
    Qu, Xiujuan
    Zhang, Chaoxu
    Fan, Yibo
    Che, Xiaofang
    Liu, Yunpeng
    CANCER RESEARCH, 2019, 79 (13)
  • [14] Exosomal PD-L1 and T lymphocyte status predict the effect of anti-PD-1 therapy
    Zhang, C.
    Qu, X.
    Fan, Y.
    Zhang, M.
    Che, X.
    Hou, K.
    Liu, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1753 - 1753
  • [15] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Hiro Sato
    Noriyuki Okonogi
    Takashi Nakano
    International Journal of Clinical Oncology, 2020, 25 : 801 - 809
  • [16] Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
    Yang, Bo
    Liu, Tingjun
    Qu, Yang
    Liu, Hangbo
    Zheng, Song Guo
    Cheng, Bin
    Sun, Jianbo
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [17] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Sato, Hiro
    Okonogi, Noriyuki
    Nakano, Takashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 801 - 809
  • [18] Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
    Lee, Heng-Huan
    Wang, Ying-Nai
    Xia, Weiya
    Chen, Chia-Hung
    Rau, Kun-Ming
    Ye, Leiguang
    Wei, Yongkun
    Chou, Chao-Kai
    Wang, Shao-Chun
    Yan, Meisi
    Tu, Chih-Yen
    Hsia, Te-Chun
    Chiang, Shu-Fen
    Chao, K. S. Clifford
    Wistuba, Ignacio I.
    Hsu, Jennifer L.
    Hortobagyi, Gabriel N.
    Hung, Mien-Chie
    CANCER CELL, 2019, 36 (02) : 168 - +
  • [19] Efficacy of anti-PD-1/PD-L1 antibody after discontinuation of antibody due to non-progressive disease in NSCLC Patients
    Inoue, Takako
    Tachihara, Motoko
    Tamiya, Motohiro
    Akazawa, Yuki
    Uenami, Ken
    Urata, Yoshiko
    Hattori, Yoshihiro
    Okuda, Chiyuki
    Katakami, Nobuyuki
    Negoro, Shunichi
    ANNALS OF ONCOLOGY, 2017, 28
  • [20] Anti-PD-1 monoclonal antibody Cancer immunotherapy
    da Silva, R. Moreira
    DRUGS OF THE FUTURE, 2014, 39 (01) : 15 - 24
12345